Alzamend Neuro to Present at Sequire Investor Summit; Company to Report Progress with Clinical Trials to be Initiated in 2025 and Expected Milestones ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Dementia cases in the U.S. are expected to double by 2060, with an estimated one million people diagnosed per year, according ...

Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 ...

The enduring scientific interest in the brain is highlighted by the donation of Charles Babbage’s brain in 1871. Babbage’s ...